CD90 Sorting for Myotube Induction from Urine-Derived Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Human urine-derived cells are a heterogeneous population, making it difficult to efficiently induce myotubes for drug evaluation and disease study, as not all cells have high muscle differentiation potential, and a specific cell surface marker for high muscle differentiation potential has been lacking.
Innovation Solution
Identification of CD90 as a cell surface marker for human urine-derived cells with high muscle differentiation potential, allowing for the separation and induction of myotubes from these cells, which can be used for drug evaluation and disease studies without producing induced pluripotent stem cells or exposing cells to epigenetic control compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If human urine-derived cells are used for myotube induction, then noninvasive cell collection is achieved, but the heterogeneous nature of the cell population reduces induction efficiency
Solution Approach 1:
The patent extracts and isolates CD90-positive cells from the heterogeneous urine-derived cell population using flow cytometry-based cell sorting. This extraction process separates the subset of cells with high muscle differentiation potential from the rest, thereby maintaining the noninvasive collection advantage while significantly improving myotube induction efficiency by working only with the relevant cell subset.
Solution Approach 2:
The patent applies local quality by identifying and selecting cells with specific surface characteristics (CD90 expression) that correlate with high muscle differentiation potential. By focusing on this specific subset of cells rather than treating the entire heterogeneous population uniformly, the method optimizes induction efficiency for those cells most likely to become myotubes.
2Quantity of substance
If the entire heterogeneous cell population is used for myotube induction, then all urine-derived cells are utilized, but induction efficiency is reduced due to varying muscle differentiation potential
Solution Approach 1:
The patent extracts CD90-positive cells from the total urine-derived cell population, separating them from CD90-negative cells. This extraction allows the method to focus on the subset of cells with high muscle differentiation potential, thereby improving induction efficiency while still utilizing a significant portion of the total cell population (approximately 10-30% of UDCs are CD90-positive).
Solution Approach 2:
The patent identifies and selects cells with specific surface characteristics (CD90 expression) that correlate with high muscle differentiation potential. By focusing on this specific subset of cells rather than treating the entire heterogeneous population uniformly, the method optimizes induction efficiency for those cells most likely to become myotubes.
3Productivity
If cell sorting by CD90 is performed, then muscle differentiation potential is enhanced, but additional separation steps are required
Solution Approach 1:
The patent uses CD90, a cell surface marker, as an intermediary to indirectly identify and select cells with high muscle differentiation potential. Instead of directly measuring differentiation potential or using complex multi-parameter sorting, the method employs CD90 expression as a proxy marker that correlates with muscle differentiation capability, simplifying the sorting process while maintaining high productivity.
Solution Approach 2:
The patent changes the selection parameter from general cell population to specific CD90-positive cell subset. By using flow cytometry to sort based on CD90 surface marker expression, the method transforms the heterogeneous population into a homogeneous subset with enhanced muscle differentiation potential, achieving high productivity through a relatively simple single-parameter sorting approach.
Data Source
AI summary
Disclosed are a cell population of human urine-derived cells positive for CD90, a cell population of myotubes induced from the cell population of the human urine-derived cells positive for CD90, and a method for producing a myotube derived from the human urine-derived cell, comprising a step of separating the human urine-derived cells positive for CD90.